The controversy surrounding Cassava Sciences and its experimental Alzheimer's drug, simufilam, has garnered significant attention within the medical and research communities, as well as among regulatory bodies and patient advocacy groups. Allegations of data manipulation and scientific
Biopharmaceutical companies face numerous challenges in the quest to develop and commercialize effective oncology drugs. The intricate journey from Phase 1 trials to market approval often sees only a small fraction of drugs succeeding, and even when they do, understanding how new drug approvals
Thailand's biotechnology sector is undergoing a transformative shift, driven by strategic partnerships, cutting-edge innovations, and robust support for entrepreneurs. The Thailand Center of Excellence for Life Sciences (TCELS) is at the forefront of this transformation, spearheading
The relationship between Big Pharma and AI-focused biotechs is at a crossroads, with implications that could redefine the landscape of drug research and development. For years, the promise of artificial intelligence (AI) has enticed major pharmaceutical companies to collaborate with nimble biotech
The world of medical and pharmaceutical advancements is frequently marked by innovative partnerships that push the boundaries of what is possible in patient care. One such collaboration has recently emerged between Excellos Inc. and Galapagos. These two entities have teamed up to enhance the
LakeShore Biopharma Co Ltd. (NASDAQ: LSB) has attracted significant attention in the stock market due to its highly volatile performance over the past year. Investors have witnessed dramatic shifts in the company's stock price, reflecting a mixed sentiment among stakeholders about the
Bioprocessing, with its roots in the early days of microbial fermentation, now stands as a fundamental pillar in the realm of modern biotechnology. This sophisticated field merges biological and engineering principles to harness the power of living organisms in producing a vast array of valuable
Cell and gene therapies (C>s) have emerged as revolutionary treatments, particularly for rare diseases with limited treatment options. The rapid growth in demand for these personalized medicines has posed significant challenges for the industry, particularly in maintaining product
Mereo BioPharma Group, a dynamic player in the biopharmaceutical sector specializing in oncology and rare disease therapeutics, is undergoing notable shifts in institutional investments. Investors closely monitoring Mereo BioPharma Group will find a mixed landscape marked by both reductions and
In a significant step towards fostering environmental responsibility in the pharmaceutical sector, Tower Cold Chain has launched a new sustainability hub designed to help pharmaceutical manufacturers improve their environmental, social, and governance (ESG) practices. This initiative highlights the
